Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% and ARQ-151 Cream 0.15% Administered QD (Quaque Die) in Adolescent and Adult Subjects With Atopic Dermatitis

NCT03916081 is registered in ClinicalTrials.gov with Arcutis Biotherapeutics, Inc. as lead sponsor.

NCT NCT03916081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03916081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% and ARQ-151 Cream 0.15% Administered QD (Quaque Die) in Adolescent and Adult Subjects With Atopic Dermatitis
Lead sponsor
Arcutis Biotherapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2019
Completion date
November 4, 2019
Enrollment
136 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis